Aequus Pharmaceuticals (Aequus Pharmaceuticals) EV-to-EBIT : -3.34 (As of May. 05, 2024)

Aequus Pharmaceuticals EV-to-EBIT Chart

Aequus Pharmaceuticals Annual Data
	Trend	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22
EV-to-EBIT		Get a 7-Day Free Trial					-4.45	-4.54	-26.68	-11.07	-2.38

Aequus Pharmaceuticals Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Sep23
EV-to-EBIT	Get a 7-Day Free Trial															-6.36	-5.04	-3.62	-2.38	-4.88

Competitive Comparison of Aequus Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Aequus Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aequus Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aequus Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Aequus Pharmaceuticals's EV-to-EBIT falls into.

Aequus Pharmaceuticals EV-to-EBIT Calculation

Aequus Pharmaceuticals's EV-to-EBIT for today is calculated as:

Aequus Pharmaceuticals's current Enterprise Value is $4.33 Mil.
Aequus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aequus Pharmaceuticals  (OTCPK:AQSZF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Aequus Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Aequus Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2023 was $6.22 Mil.
Aequus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aequus Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Aequus Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Aequus Pharmaceuticals (Aequus Pharmaceuticals) Business Description